Brevibacillus laterosporus

probiotic

At a glance

Best for
no established human use; data are preclinical
Typical dose
not established for humans
Time to effect
Uncertain
Main caution
lacks human safety and efficacy data as a probiotic; benefit is unproven
Evidence strength: Very limited; in-vitro and environmental/biocontrol studies only

What is it

Brevibacillus laterosporus is a spore-forming soil bacterium that has been investigated as a biocontrol agent and, in some products, marketed as a probiotic. Its proposed activity is producing antimicrobial compounds active against other microbes. There are essentially no controlled human trials, and its use as a human probiotic is not well established or validated for safety.

Is it worth it for you?

Worth considering if…

  • you accept that human evidence is essentially absent

Probably skip if…

  • you want an evidence-based probiotic (choose well-studied strains)
  • you are immunocompromised
  • you expect a proven digestive or immune benefit

Evidence at a glance

GoalEvidenceEffectBest fitTime
antimicrobial activity against other microbesMixedUnknown in humansnot establishedUncertain

Evidence for 1 use

AI-assisted evidence assessment — talk to your doctor before relying on any single supplement.

antimicrobial activity against other microbes

Mechanism only
Mixed

Brevibacillus laterosporus produces antimicrobial substances and has been studied as a biocontrol agent against insects, fungi, and some bacteria in laboratory and environmental settings. There are no robust human trials demonstrating a probiotic or therapeutic benefit, and its safety as an ingested human probiotic is not well characterized. Any human benefit is purely speculative based on microbial mechanisms.

Effect size: Unknown in humans
Time to effect: Uncertain
Best fit: not established

Bottom line: B. laterosporus has antimicrobial activity in the lab, but there is no credible human evidence supporting its use as a probiotic.

Evidence is mixed

Evidence is confined to in-vitro and biocontrol studies; human efficacy and safety data are absent.

How to take it

Typical dose
no validated human dose
Timing
as directed by the product
With food
as directed
How long to try
short trial only, given limited data

What to track

  • digestive comfort
  • any adverse symptoms

Safety

Common side effects

not characterized in humans

Serious risks

  • unknown safety profile as an ingested human probiotic

Who should avoid it

  • immunocompromised people
  • critically ill people
  • people with central venous catheters

Pregnancy & breastfeeding

No human safety data; avoid in pregnancy.

Choosing a product

Look for

  • clearly identifies the strain
  • discloses CFU count and viability
  • third-party verification of identity and purity

Be skeptical of

  • treats infections
  • restores gut health
  • human benefit claims based on biocontrol or lab data

References by claim

antimicrobial activity against other microbes

  • Jiang et al., 2017PubMed (2017) link
  • Weng et al., 2025PubMed (2025) link

Track Brevibacillus laterosporus with Pilora

Set up dose reminders, check interactions, and join the community in the Pilora iPhone app.

Coming to App Store
Evidence-based·Last reviewed May 30, 2026·Evidence current as of May 30, 2026·How we grade evidence

Disclaimer: These statements have not been evaluated by the FDA. This page is educational, not a substitute for personalized medical advice. Evidence grades are AI-assisted assessments — talk to your doctor before starting any new supplement, especially if you’re pregnant, breastfeeding, on medications, or managing a chronic condition.